Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov ID: NCT02573870

Public ClinicalTrials.gov record NCT02573870. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD

Study identification

NCT ID
NCT02573870
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
63 participants

Conditions and interventions

Interventions

  • Batefenterol + Fluticasone Furoate Drug
  • Placebo Drug
  • Albuterol Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2015
Primary completion
Jul 4, 2016
Completion
Jul 4, 2016
Last update posted
Jul 20, 2020

2015 – 2016

United States locations

U.S. sites
10
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85006
GSK Investigational Site Hollywood Florida 33021
GSK Investigational Site Baltimore Maryland 21225
GSK Investigational Site Charlotte North Carolina 28207
GSK Investigational Site Gastonia North Carolina 28054
GSK Investigational Site Grove City Ohio 43123
GSK Investigational Site Easley South Carolina 29640
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Seneca South Carolina 29678
GSK Investigational Site McKinney Texas 75069

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02573870, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 20, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02573870 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →